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Atopic dermatitis (AD) is an inﬂammatory skin disease in which pathogenesis chemokines are partially involved. The aim of
the paper was to assess the serum level of CXCL-9, CXCL-10, CXCL-11, CXCL-12, CCL-17, CCL-20, CCL-21, CCL-22, CCL-
27, and IL-18 chosen in AD patients by ELISA assay. Forty patients (mean age 11.4 years old) with AD and 50 healthy controls
were enrolled into the study. The patients and controls were divided into two age categories: under 10 years old (Group 1 and
Control 1) and over 10 years old (Group 2 and Control 2). Signiﬁcantly lower serum concentration of CXCL-9, CXCL-10, CCL-
17, and IL-18 and higher concentration of CXCL-12 and CCL-27 were found in Group 1 when compared to Control 1. In Group
2 serum concentration of CXCL-12, CCL-17, CCL-22 was higher than in Control 2. The obtained results indicate the imbalance
in chemokine serum levels in AD what suggests their role in the disease pathogenesis.
Copyright © 2009 Joanna Narbutt et al. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
cited.
1.Introduction
Atopic dermatitis (AD) is a chronic and recurrent disease
which concerns 10–20% of population [1]. The onset of AD
is usually before 2 years old, and in approximately 60% of
the patients skin lesions of diﬀerent intensity remain for the
whole life [2]. AD is characterized by typical morphology
and distribution of skin lesions, severe pruritus, and familial
atopic history. Clinical phenotype of the disease depends on
multiple interactions between genetic and immunological
disturbances, epidermal barrier impairment, and environ-
mental factors [3, 4].
Histopathologically skin lesions present mainly with a
dermal inﬁltrate of mainly CLA+ memory T cells and
Langerhans cells [5]. Leukocyte traﬃcking into the skin
in AD patients is probably mainly regulated by adhe-
sion molecules and chemoattractive proteins, so-called
chemokines [6, 7]. Chemokines are small secreted proteins
involved in migration and activation of lymphocytes T.
Recently published papers indicate their role in pathogenesis
of multiple inﬂammatory skin diseases including atopic
dermatitis [8].
InactiveskinlesionsinthecourseofADinﬁltratesofTh-
2 lymphocytes releasing IL-4 and/or IL-13 are found. These
cells express CCR4, CCR8, and CRTH2 receptors on their
surface. Lymphocytes Th-2 migration is selectively induced
by such chemokines as CCL17 and CCL22, which are highly
overexpressedonthekeratinocytesinADpatientsepidermis.
These phenomena lead in a consequence to development
of local inﬂammation [9, 10]. In the studies analyzing
serum concentration of these chemokines, increased levels
of CCL-17 and CCL-22 were found in AD patients, and
their concentrations strongly correlated with disease activity
[11, 12].
Shimada et al. [13] found increased levels of Th-2 (CCL-
17 and CCL-22) and Th-1 (CXCL-9) chemokines in AD
patients. They also found a positive correlation between
Th-2 chemokines serum level and total IgE concentration,2 Mediators of Inﬂammation
moreover Th-2 chemokines correlated with Th-1 ones. In
another study performed in infantile AD patients (mean
age 4.5 months) also increased levels of CCL-17, CCL-
20, CCL-27 were observed which strongly correlated with
disease activity, however the most prominent correlation was
observed for CCL-27 [14].
Interleukin (IL)-18 is involved in pathogenesis of type-
2 helper cells-mediated diseases including atopic dermatitis.
According to literature, its serum concentration is signiﬁ-
cantly elevated in AD patients and correlates with clinical
severity of the disease [15, 16].
Most literature data point out an important role of
chemokinenetworkimbalanceindevelopmentofatopicder-
matitis,howevertherearescarcedataonthecomplexanalysis
of serum levels of Th-1- and Th-2-derived chemokines in
AD patients. Thus, the aim of the paper was to assess the
serumlevelofCXCL-9,CXCL-10,CXCL-11,CXCL-12,CCL-
17, CCL-20, CCL-21, CCL-22, CCL-27, IL-18 in two AD
patient groups, below and over 10 years old. Additionally
we analyzed serum levels of the chosen chemokines in two
groups of healthy volunteers, aged-matched, to note any age-
dependent variations in healthy population.
2.MaterialandMethods
2.1. Patients. Forty patients (mean age 11.4 years old; 23F,
15M) with AD and 50 healthy controls, age and sex matched
were enrolled into the study. AD was diagnosed according
to criteria proposed by Haniﬁn and Rajka [17]. The enrolled
patients were divided into two age categories: under 10 years
old (Group 1; n = 23) and over 10 years old (Group 2;
n = 17). According to this criterion, the control group was
divided as well (Control 1 under 10 years old n = 30; and
Control 2 over 10 years old n = 20). We used criterion of
10 years old as a cut-oﬀ point because this age is believed to
initiate adolescence life period. Clinical characteristics of the
patients are presented in Table 1.
2.2. Methods. Each patient or his/her parents gave written
informed consent before entering the study, and all the
experiments were approved by the Local Ethics Committee.
The investigations were carried out in accordance with
Declaration of Helsinki. Before entering the study the
subjects underwent thorough physical examination, and
scoring atopic dermatitis (SCORAD) index was assessed
[18]. The patients enrolled to the study had moderate AD
(mean SCORAD index 23 range 16–39). Serum samples
were analyzed for CXCL-9, CXCL-10, CXCL-11, CXCL-
12, CCL-17, CCL-20, CCL-21, CCL-22, CCL-27, IL-18
concentration with ELISA assay (R&D system, Mineapolis,
Minn, USA) according to manufacturer’s instructions. The
concentrations were calculated from the standard curve
generated by curve-ﬁtting programme.
3.StatisticalAnalysis
DatawereanalyzedusingtheMann-WhitneyUtest,andcor-
relationscoeﬃcientsweredeterminedbyusingtheSpearman
rank correlation test. A P-value of <.05 was considered as
statistically signiﬁcant.
4. Results
Median concentrations of all the analyzed proteins: CXCL-
9,CXCL-10,CXCL-11,CXCL-12,CCL-17,CCL-20,CCL-21,
CCL-22, CCL-27, IL-18 are presented in Table 2.
4.1. The Median Concentration of CXCL-9, CXCL-10, CXCL-
11, CXCL-12, CCL-17, CCL-20, CCL-21, CCL-22, CCL-27,
IL-18 in AD Patients below 10 Years Old (Group 1). The
median serum CXCL-9, CXCL-10, CCL-17, and IL-18 level
was statistically signiﬁcantly lower in AD patients from
Group 1 when compared to the Control 1 (56.7pg/mL
versus 87.3pg/mL; P = .003; 84.8pg/mL versus 98.0pg/mL;
P = .04; 405.2pg/mL versus 620.1pg/mL, P = .04;
64.8pg/mL versus 94.7pg/mL, P = .0001; resp.). In Group
1 the median serum concentration of CXCL-12 and CCL-
27 was signiﬁcantly higher than that in the Control 1 group
(2444.9pg/mL versus 2135.8pg/mL, P = .004; 463.5pg/mL
versus 406.6pg/mL, P = .03; resp.). For other chemokines
median serum values did not diﬀer statistically when com-
pared to the Control 1 (P>. 05 for all comparisons).
4.2. The Median Concentration of CXCL-9, CXCL-10, CXCL-
11, CXCL-12, CCL-17, CCL-20, CCL-21, CCL-22, CCL-
27, IL-18 in AD Patients over 10 Years Old (Group 2).
The median serum CXCL-12, CCL-17, and CCL-22 levels
were signiﬁcantly higher in AD patients from Group 2
than in the age-matched Control 2 (2553.5pg/mL versus
2361.1pg/mL, P = .01; 357.6pg/mL versus 178.3pg/mL,
P = .04; 1152.5pg/mL versus 606.1pg/mL, P = .001; resp.).
For other chemokines median serum values did not diﬀer
statistically when compared to the Control 2 (P>. 05 for
all comparisons).
4.3. Diﬀerences in the Median Concentration of CXCL-9,
CXCL-10, CXCL-11, CXCL-12, CCL-17, CCL-20, CCL-21,
CCL-22, CCL-27, IL-18 between Groups 1 and 2. Comparing
serum median levels of analyzed chemokines between two
AD groups (Group 1 versus Group 2) the only signif-
icant diﬀerence was found for CCL-20 which median
value was higher in children below 10 years old than in
older population (Group 2) (7.8pg/mL versus 7.4pg/mL;
P = .03).
4.4. Diﬀerences in the Median Concentration of CXCL-9,
CXCL-10, CXCL-11 , CXCL-12, CCL-17, CCL-20, CCL-
21, CCL-22, CCL-27, IL-18 between Controls 1 and 2.
Comparing CXCL-9, CXCL-11, CCL-17, CCL-20, CCL-22,
and IL-18 serum median concentration between Controls
1 and 2 we found signiﬁcantly higher values in younger
population (Control 1) than in Control 2 (87.3pg/mL versus
17.9pg/mL, P = .00004; 66.9pg/mL versus 43.3pg/mL,
P = .049; 620.1pg/mL versus 178.3pg/mL, P = .001;
8.3pg/mL versus 6.9pg/mL, P = .008; 1410.2pg/mL versus
606.1pg/mL, P = .00003; 94.7pg/mL versus 97.2pg/mL,Mediators of Inﬂammation 3
Table 1: Clinical chatacteristics of AD patients.
Clinical feature Group 1; n = 23 Group 2; n = 17
S e x 1 1F ,1 2M 1 1 F ,6M
Age (yr) 7.1 17.1
Disease onset
Before 6 month n = 10 Before 6 month n = 5
6m o n t h - 2y rn = 11 6 month-2 yr n = 10
Over 3 yr n = 2O v e r 3 y r n = 2
Dry skin Yes n = 20 Yes n = 17
No n = 3N o n = 0
Keratosis pilaris Yes n = 15 Yes n = 8
No n = 8N o n = 9
Hand and foot dermatitis Yes n = 4Y e s n = 2
No n = 19 No n = 15
Ichtyosis Yes n = 0Y e s n = 0
No n = 23 No n = 17
Nipple eczema Yes n = 0Y e s n = 0
No n = 23 No n = 17
Cheilitis Yes n = 12 Yes n = 11
No n = 11 No n = 6
Recurrent conjunctivitis Yes n = 12 Yes n = 11
No n = 11 No n = 6
Denni-Morgan infraorbital fold Yes n = 19 Yes n = 13
No n = 4N o n = 4
Orbital darkening Yes n = 16 Yes n = 16
No n = 7N o n = 1
Pityriasis alba Yes n = 4Y e s n = 6
No n = 19 No n = 11
Anterior Neck folds Yes n = 3Y e s n = 3
No n = 20 No n = 14
White dermographism Yes n = 9Y e s n = 2
No n = 14 No n = 15
Palmar hyperlinearity Yes n = 3Y e s n = 9
No n = 20 No n = 8
Itch when sweating Yes n = 17 Yes n = 10
No n = 6N o n = 7
Intolerance to wool Yes n = 22 Yes n = 15
No n = 1N o n = 2
Course inﬂuence by environment al and emotional factors Yes n = 16 Yes n = 9
No n = 7N o n = 8
Family history of atopy Yes n = 15 Yes n = 11
No n = 8N o n = 6
Clinical remission Yes n = 11 Yes n = 13
No n = 12 No n = 14
Mean IgE concentration (IU/mL) 173.46 257.27
% eosinophilia 4.3 3.7
P = .049; resp.). For other chemokines median serum values
didnotdiﬀerstatisticallywhencomparedtwocontrolgroups
(P>. 05 for all comparisons).
4.5. Correlations between Median Serum Levels of CXCL-
9, CXCL-10, CXCL-11, CXCL-12, CCL-17, CCL-20, CCL-
21, CCL-22, CCL-27, IL-18 in Analyzed Groups. Positive
correlation between median serum concentration of CXCL-
11 and CXCL-9 (r = 0.44, P = .03), CXCL-9 and CXCL-
10 (r = 0.42, P = .04), and CXCL-10 and IL-18 (r = 0.8,
P = .000001) was found in AD patients below 10 years old
(Group 1).
In Group 2 (AD patients over 10 years old) we found
positive correlations of the median serum levels of the4 Mediators of Inﬂammation
Table 2: Median serum concentration of analyzed chemokines in AD patients (Group 1 and Group 2) and Controls (Control 1 and 2).
Protein
Median
concentration
pg/mL
(upper/lower
quartile)
Median
concentration
pg/mL
(upper/lower
quartile)
Mdian
concentration
pg/mL
(upper/lower
quartile)
Median
concentration
pg/mL
(upper/lower
quartile)
P (statistically
signiﬁcant)
Group 1 (1)
n = 23
Control 1 (2)
n = 30
Group 2 (3)
n = 17
Control 2 (4)
n = 20
CXCL-9 56.7 (29.8/75.1) 87.3
(55.4/132.0) 34.1 (23.9/62.9) 17.9 (12.5/26.7) P1−2 = .003
P2−4 = .00004
CXCL-10 84.8 (60.8/94.3) 98.0
(76.4/135.2)
93.6
(67.4/114.9)
75.8
(63.2/112.5) P1−2 = .04
CXCL-11 52.9 (36.1/64.6) 66.9
(40.8/135.2) 57.4 (45.5/97.6) 43.2 (36.1/57.4) P2−4 = .049
CXCL-12 2444.9
(2291.2/2711)
2135.8
(1821.4/2364.7)
2553.5
(2393.9/2618.2)
2361.1
(2239.5/2430.3)
P1−2 = .004
P3−4 = .01
CCL-17 405.2
(294.4/729.9)
620.1
(369.9/889.2)
357.6
(257.4/547.3)
178.3
(132.8/304.9)
P1−2 = .04
P2−4 = .001
P3−4 = .04
CCL-20 7.8 (7.6/13.1) 8.3 (7.8/35.1) 7.4 (7.1/7.9) 6.9 (5.9/7.8) P1−3 = .03
P2−4 = .008
CCL-21 158.1
(108.8/234.9)
175.5
(85.5/243.3)
158.1
(126.9/209.8)
160.7
(140.4/188.4)
P<. 05 for all
comparisons
CCL-22 1147.5
(908.6/1395.3)
1410.2
(1010.5/1612.8)
1152.5
(945.3/1390.5)
606.1
(571.3/726.1)
P2−4 = .00003
P3−4 = .001
CCL-27 463.5
(406.1/519.6)
406.6
(326.8/452.9)
487.1
(367.1/628.3)
385.0
(342.7/544.3) P1−2 = .03
IL-18 64.8 (54.1/73.1) 94.7
(80.6/124.9) 63.3 (56.9/83.7) 77.2 (60.4/96.3) P1−2 = .0001
P2−4 = .049
analyzed proteins for the following parameters: CXCL-11
and CXCL-9 (r = 0.85, P = .00001), CXCL-11 and CXCL-
10 (r = 0.8, P = .00006), CXCL-11 and CCL-20 (r = 0.96,
P<. 001), CXCL-9 and CXCL-10 (r = 0.59, P = .01), CXCL-
9 and CCL-20 (r = 0.84, P = .00002), CXCL-10 and CCL-
20 (r = 0.79, P = .0002), and CCL-17 and IL-18 (r = 0.5,
P = .03). Moreover in this group we observed a positive
correlation between serum median concentration of CCL-22
and patients’ age (r = 0.52, P = .003).
In Control 1 we found positive correlations between
serum levels of the following chemokines: CXCL-11 and
CCL-21 (r = 0.4, P = .03), CXCL-11 and CCL-22 (r = 0.37,
P = .04), CXCL-11 and CCL-17 (r = 0.36, P = .048), CXCL-
9 and CXCL-10 (r = 0.47, P = .008), CCL-17 and CCL-
22 (r = 0.68, P = .00003). Contrary, negative correlation
between serum level of CCL-21 and CXCL-9 (r =− 0.36,
P = .04) was noted. Analysing correlation between serum
chemokine levels and patients’ age we found a negative link
for CCL-21 and CCCL-22 (r =− 0.5, P = .004; r =− 0.36,
P = .048; resp.).
In the Control 2 positive correlations were found only
between CXCL-10 and CCL-21, and CXCL-17 and CCL-20
(r = 0.84, P = .002; r = 0.9, P = .0003; resp.).
Taking the whole AD group (Group 1 and 2) into
statistical analysis we found no correlation between serum
levels of analyzed parameters and patients’ age, while doing
the same analysis for whole control group (Control 1 +
Control 2) we found negative correlations between age of the
subjectsandthefollowingproteins:CCL-17,CCL-22andIL-
18 (r =− 0.38, P = .01; r =− 0.67, P = .000002; r =− 0.3,
P = .045; resp.).
4.6. Correlations between Median Serum Levels of CXCL-
9, CXCL-10, CXCL-11, CXCL-12, CCL-17, CCL-20, CCL-
21, CCL-22, CCL-27, IL-18 and IgE Concentration and
Eosinophilia in Analyzed Groups. In Group 1 a positive
correlation between mean total IgE serum concentration and
CCL-20 was found (r = 0.52, P = .009), while in Group
2 it was found for CCL-17 (r = 0.68, P = .002), CCL-27
(r = 0.049, P = .046) and IL-18 (r = 0.58, P = .01).
Analysing all the subjects from AD group (Group 1 and
2) IgE serum concentration correlated positively only with
CCL-17 (r = 0.49, P = .01).
In AD patients below 10 years old (Group 1) a positive
correlation between eosinophilia and CCL-20 (r = 0.53, P =
.009)andIL-18(r = 0.45,P = .03)wasnotedwhileinGroup
2 eosinophilia correlated positively with CCL-27 (r = 0.52,
P = .03). Analyzing all the subjects from AD group (Groups
1 and 2) eosinophilia correlated positively only with CCL-22
(r = 0.36, P = .02).Mediators of Inﬂammation 5
5. Discussion
Chemokines are small proteins which contribute to leuko-
cytestraﬃckingintotheskin.CXCL-9,CXCL-10,andCXCL-
11 recruit lymphocytes mainly to Th-1 type inﬂammatory
sites while chemokines such as CCL-11, CCL-17, CCL-22
lead to Th-2 dominated pattern of cell recruitment [19].
CCL-27 selectively attracts CLA + memory T cells via CCR-
10 receptor expressed on these cells [20, 21].
Recent data indicate increased serum level of CCL-27 in
AD patients, correlating with disease activity, what suggests
its role in inﬂammatory process [22, 23]. Hon et al. [23]
assessedCCL-27serumlevelinchildrenaged1–11yearswith
mean SCORAD [29.7] and found its higher serum concen-
tration, what is in line with our results, however contrary
to the authors we found no correlation between CCL-27
and CCL-17 and CCL-22 concentrations. Also level of CCL-
17 in Group 1, although statistically diﬀerent than that in
Control 1, was lower in AD patients than in healthy ones.
Such discrepancy between our results and published ones in
other papers, indicates that it is still unclear either increased
or decreased CCL-17 level is a characteristic for AD patients,
however its distinct level when compared to the control
groups testiﬁes its role in AD pathogenesis. In our study
similar observations concern CXCL-9, CXCL-10, and IL-18.
Interestingly, in Group 2 (patients over 10 years old) we
found elevated serum levels of CCL-17, CCL-22, and CXCL-
12 what also proves their role in AD pathogenesis. Other
authors also showed signiﬁcantly higher concentrations of
CCL-17, CCL-22, and eotaxin in AD patients than in healthy
control. They found positive correlations between serum
level of CCL-17 and CCL-22 and total IgE concentration
and as well these chemokines correlated positively with
SCORAD index [24]. In our study CCL-17, CCL-27 and IL-
18 serum levels correlated positively with total IgE in Group
2, and eosinophilia correlated positively with CCL-27. Hon
et al. [25] revealed correlation between IgE and CCL-17
and eosinophiles count but not with CCL-27 what is only
partially consistent with our results.
In skin biopsies taken from AD patients CCL-20 expres-
sion is observed in basal layer of epidermis. This protein
is a strong chemoattractant for immature dendritic cells
and memory T cells via interactions with CCR6. CCL20
may be induced on keratinocytes under proinﬂammatory
cytokinessuch:IL-1αor TNF-α. Inhealthyepidermis CCL20
is constitutively expressed in epidermal basal layer, however
its expression is signiﬁcantly lower than in inﬂammatory
skin [26, 27]. These data prove CCL-20 role in AD patho-
genesis. Although we found no diﬀerences between CCL-
20 serum concentration in AD patients and controls, its
higher concentration was observed in Group 1 than in
Group 2. Moreover, in younger population (Group 1) IgE
and eosinophilia correlated with CCL-20. To our knowledge,
there are no data in literature on the subjects, however
observed association and data mentioned above provide its
role in AD pathogenesis in younger population and its level
normalization in line with the age.
To our knowledge, there are no data on CCL-21 serum
levels in AD patients. We examined this chemokine as
it is strongly chemoattractive to lymphocytes T, enhances
expression of LFA-1 on these cells, and mediates cell-to-
cell adhesion. Besides, CCL-21 and CCR7 receptor inﬂuence
naive T cell migration to lymph nodes where antigen is
presented. In healthy skin immunostaining for CCL21 is
negative, however it is expressed on dermal endothelial
cells in atopic dermatitis [28]. Weninger et al. [29] showed
that CCL21 expression on blood vessels positively correlated
with the presence of CD45RA+ T cells in the inﬂamma-
tory inﬁltrate. Although CCL21 expression was found in
inﬂammatory T cell-mediated diseases, its exact role in
their pathogenesis is not elucidated. Our study in which
we found no diﬀerences in CCL-21 serum concentration
between AD patients and controls does not prove the role
of the chemokine in AD pathogenesis.
To assess chemokines serum levels depending on age
in healthy population, we attempted to check diﬀerences
between Controls 1 and 2. Our analysis revealed a distinct
pattern in healthy population than that in AD groups.
In younger healthy population we found increased levels
of CXCL-9, CXCL-11, CCL-17, CCL-20, CCL-22, and IL-
18 while comparing Groups 1 and 2 the only signiﬁcance
concerned CCL-20.
In the study published by Furusyo et al. [30]n o
diﬀerences in serum level of CCL-17 between AD patients
(children 0–5 years old) and age-matched healthy control
were revealed. Moreover in healthy children they observed
that serum CCL-17 concentration decreased with age while
serum CCL-17 in AD patients did not diﬀer in relation to
age. The authors revealed strong dependence between CCL-
17 serum concentration and AD course during childhood.
These data are partially consistent with ours, as we also
observed a decrease in CCL-17 with age in healthy popu-
lation and no such age-dependence in AD group. To our
knowledge there are no more data analyzing chemokines
in this aspect. Lack of these naturally occurring changes in
chemokine serum levels in AD patients provides their role
in the disease pathogenesis. This hypothesis may be partially
proven by our observation on the lack of correlation between
age and chosen chemokines serum levels in AD patients and
the presence of multiple negative correlations between CCL-
17, CCL-22, IL-18, and age in the whole control group.
Concluding, we may assume that in younger children
withADadecreasedserumlevelofTh-1-derivedchemokines
is one of the factors involved in the disease development.
The imbalance between Th-1 and Th-2 is probably involved
in AD pathogenesis as well, what in our paper is espe-
cially emphasized by diﬀerences in chemokine concentration
between two AD groups and two age-matched controls. Our
study, similar to others, revealed signiﬁcant changes between
chemokine levels in AD patients and controls, however
not always consistent with other authors what may result
from two main reasons. The ﬁrst one is a new aspect of
AD pathogenesis, mostly focused now on the impairment
of epidermal barrier and innate immune defense as the
primary causative factors involved in AD; only these dis-
turbances lead secondary to induction of adaptive immune
response, inﬂammation development involving chemokines
disturbances. The second reason may be the lack of objective6 Mediators of Inﬂammation
andstandardizedmethodforADclinicalevaluation,thusthe
patients enrolled to the studies in diﬀerent centers, although
with the same SCORAD index, may have a little diﬀerent
clinical picture.
Based on literature and our results we conclude that
chemokine imbalance is involved in AD pathogenesis, how-
ever discrepancies obtained in many studies and relatively
small number of the patients included in our study do not
allow to draw equivocal conclusions. In our opinion further
studies correlating chemokine serum levels, their expression
intheskin,andADclinicalpicturearerequiredandprobably
will give new light on the disease pathogenesis.
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